The clinical significance of ATX measurement has been well established in Japan, where its testing has been covered by national health insurance since 2018 for monitoring patients with such chronic hepatitis conditions as metabolic dysfunction–associated steatotic liver disease (MASLD) and primary biliary cholangitis [9, 10]. Here, ENPP2 is linked to primary biliary cholangitis.